Patents by Inventor Christopher Neil Farthing
Christopher Neil Farthing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9079914Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: July 21, 2010Date of Patent: July 14, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: John Mark Ellard, Christopher Neil Farthing, Adrian Hall
-
Patent number: 8940734Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: October 18, 2013Date of Patent: January 27, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Adrian Hall, Christopher Neil Farthing, Jose Luis Castro Pineiro
-
Publication number: 20140142091Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: October 18, 2013Publication date: May 22, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Adrian Hall, Christopher Neil Farthing, Jose Luis Castro Pineiro
-
Patent number: 8592408Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: November 26, 2012Date of Patent: November 26, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Adrian Hall, Christopher Neil Farthing
-
Patent number: 8338407Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: January 20, 2012Date of Patent: December 25, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Adrian Hall, Christopher Neil Farthing
-
Publication number: 20120202804Abstract: A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: July 21, 2010Publication date: August 9, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: John Mark Ellard, Christopher Neil Farthing, Adrian Hall
-
Publication number: 20120190672Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C?N; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: January 20, 2012Publication date: July 26, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Adrian Hall, Christopher Neil Farthing, Jose Luis Castro Pineiro
-
Patent number: 8178552Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.Type: GrantFiled: August 5, 2009Date of Patent: May 15, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Piotr Pawel Graczyk, Paschalis Dimopoulos, Afzal Khan, Gurpreet Singh Bhatia, Christopher Neil Farthing
-
Patent number: 7951802Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.Type: GrantFiled: August 5, 2009Date of Patent: May 31, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Piotr Pawel Graczyk, Paschalis Dimopoulos, Christopher Neil Farthing, Gurpreet Singh Bhatia, Afzal Khan
-
Publication number: 20100069354Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.Type: ApplicationFiled: August 5, 2009Publication date: March 18, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Piotr Pawel GRACZYK, Paschalis DIMOPOULOS, Afzal KHAN, Gurpreet Singh BHATIA, Christopher Neil FARTHING
-
Publication number: 20100069358Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.Type: ApplicationFiled: August 5, 2009Publication date: March 18, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Piotr Pawel GRACZYK, Paschalis DIMOPOULOS, Christopher Neil FARTHING, Gurpreet Singh BHATIA, Afzal KHAN
-
Patent number: 7381734Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.Type: GrantFiled: July 22, 2005Date of Patent: June 3, 2008Assignee: Tularik LimitedInventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
-
Patent number: 7157585Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.Type: GrantFiled: May 11, 2005Date of Patent: January 2, 2007Assignee: Tularik LimitedInventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
-
Patent number: 7074934Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.Type: GrantFiled: June 12, 2001Date of Patent: July 11, 2006Assignee: Tularik LimitedInventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
-
Patent number: 7067516Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.Type: GrantFiled: December 12, 2001Date of Patent: June 27, 2006Assignee: Tularik LimitedInventors: Sarah Elizabeth Lively, Martin James Harrison, Neil Jason Naylor, Christopher Neil Farthing, Bohdan Waszkowycz
-
Patent number: 6916957Abstract: Compounds of formula (I) where R5, R6a, each X, L, Cy and Lp are as defined in the specification, are tryptase inhibitors useful as antiinflammatory agents.Type: GrantFiled: December 13, 2000Date of Patent: July 12, 2005Assignee: Tularik LimitedInventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
-
Publication number: 20040116439Abstract: Compounds of formula (I) 1Type: ApplicationFiled: June 2, 2003Publication date: June 17, 2004Inventors: Sarah Elizabeth Lively, Martin James Harrison, Neil Jason Naylor, Christopher Neil Farthing, Bohdan Waszkowycz
-
Publication number: 20030216403Abstract: 1Type: ApplicationFiled: May 14, 2003Publication date: November 20, 2003Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin James Harrison, Christopher Neil Farthing, Keith Michael Johnson
-
Publication number: 20030018059Abstract: Compounds of formula (I) 1Type: ApplicationFiled: June 3, 2002Publication date: January 23, 2003Inventors: Sarah Elizabeth Lively, Bohdan Waszkowycz, Martin JAMES Harrison, Christopher Neil Farthing, Keith Michael Johnson